Abstract
Rett syndrome (RTT) is a rare, X-linked neurodevelopmental disorder that occurs due to mutations in the gene that codes for the transcription factor methyl CpG-binding protein 2 (MECP2). Several studies are now examining potential therapies for RTT based on the basic science insights from such experiments on mice with MeCP2 deficiency. This recent study provides pre-clinical data suggesting that fingolimod, a sphingosine-1 phosphate receptor modulator that can increase levels of brain-derived neurotrophic factor, can also reduce signs of disease in an RTT mouse model.